Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100176 | 0.82 | CHRM4 (0.32) | CHRM4ATM | |
| SCHEMBL4242392 | 0.81 | CHRM4 (0.49) | DPP4CYP3A4CHRM4 | |
| SCHEMBL8091569 | 0.72 | CYP3A4 (0.49) | DPP4CYP3A4CHRM4GRIN1GRIN2B | |
| SCHEMBL8100326 | 0.72 | HTR1A (0.35) | — | |
| SCHEMBL8100848 | 0.71 | HRH3 (0.44) | DPP4CYP3A4CHRM4 | |
| SCHEMBL13945453 | 0.70 | CYP3A4 (0.47) | DPP4CYP3A4CHRM4 | |
| SCHEMBL8094629 | 0.70 | DPP4 (0.47) | DPP4CYP3A4CHRM4 | |
| SCHEMBL13969375 | 0.70 | HTR1D (0.42) | DPP4CYP3A4CHRM4 | |
| SCHEMBL13945403 | 0.68 | CYP3A4 (0.42) | DPP4CYP3A4 | |
| SCHEMBL4241073 | 0.67 | CHRM4 (0.42) | DPP4CYP3A4CHRM4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | DPP4 3459/4885CYP3A4 1573/4885CHRM4 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.